ReCODE creates a personalized plan based on your medical history, genetics, and biomarkers to restore brain health by addressing the root causes of cognitive decline. ReCODE is built on decades of groundbreaking research by Dr. Dale Bredesen, a leading expert in Alzheimer’s disease.
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
The ReCODE diet, called "Ketoflex 12/3", consists of being in ketosis, eating high amounts of fiber, eating within a 12 hour window, and stop eating at least 3 hours before bed.
ReCODE is a comprehensive and personalized multi-therapeutic program for reversing symptoms of cognitive decline and optimizing brain health, using a targeted algorithm based on biochemical and genetic risk factors for cognitive decline.
Recode (stylized as recode; formerly Re/code) [1] was a technology news website that focused on the business of Silicon Valley. Walt Mossberg and Kara Swisher founded it in January 2014, after they left Dow Jones and the similar website they had previously co-founded, All Things Digital.
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics.
The ReCODE Program is the first and only approach shown in studies to reverse cognitive decline. Research shows drugs don't work.
What is the ReCODE Program? The ReCODE™ (Reversal of Cognitive Decline) program, developed by Dr. Dale Bredesen, is a cutting-edge approach to slowing or reversing cognitive decline.